Publication:
Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score-matched cohort study.

Simple item page
dc.contributor.authorMirioglu, Safak
dc.contributor.authorDirim, Ahmet Burak
dc.contributor.authorBektas, Murat
dc.contributor.authorDemir, Erol
dc.contributor.authorTor, Yavuz Burak
dc.contributor.authorOzluk, Yasemin
dc.contributor.authorKilicaslan, Isin
dc.contributor.authorOto, Ozgur Akin
dc.contributor.authorYalcinkaya, Yasemin
dc.contributor.authorCaliskan, Yasar
dc.contributor.authorArtim-Esen, Bahar
dc.contributor.authorYazici, Halil
dc.contributor.authorInanc, Murat
dc.contributor.authorTurkmen, Aydin
dc.contributor.authorGul, Ahmet
dc.contributor.authorSever, Mehmet Sukru
dc.date.accessioned2023-05-16T14:51:41Z
dc.date.available2023-05-16T14:51:41Z
dc.date.issued2023-05-03T21:00:00Z
dc.description.abstractData on use of interleukin (IL)-1 blockers in kidney transplant recipients (KTRs) with familial Mediterranean fever (FMF) are very limited. We aimed to evaluate the efficacy and safety of anakinra and canakinumab in the transplantation setting.
dc.description.abstractIn this retrospective cohort study, we included KTRs who suffered from AA amyloidosis caused by FMF and treated with anakinra or canakinumab (study group, n = 36). Using propensity score matching, we selected 36 patients without FMF or amyloidosis from our database of 696 KTRs as the control group. Primary outcomes were patient and graft survival. Biopsy-confirmed graft rejection, changes in estimated glomerular filtration rate (eGFR), high-sensitivity CRP (hsCRP), erythrocyte sedimentation rate (ESR), proteinuria and number of monthly attacks were secondary outcomes.
dc.description.abstractAll KTRs with FMF began IL-1 blocker therapy with anakinra and nine (25%) were switched to canakinumab. Overall death was more frequent in the study group (19.4% vs 0%) (P = .005); however, overall graft loss was comparable between study (27.8%) and control groups (36.1%) (P = .448). Five- and 10-year graft survival rates were significantly higher in the study group (94.4% and 83.3%, respectively) than in the control group (77.8% and 63.9%, respectively) (P = .014 and P < .001, respectively). Rejections were numerically lower in study group (8.3% vs 25%), but it did not reach to statistical significance (P = .058). When compared with the pre-treatment period, with IL-1 blockers, the number of attacks per month (P < .001), and eGFR (P = .004), hsCRP (P < .001) and ESR (P = .026) levels were lower throughout the follow-up, whereas proteinuria levels were not.
dc.description.abstractAnakinra and canakinumab are effective in KTRs suffering from FMF; however, the mortality rate may be of concern.
dc.identifier.pubmed36542475
dc.identifier.urihttps://hdl.handle.net/20.500.12645/37871
dc.language.isoen
dc.subjectamyloidosis
dc.subjectanakinra
dc.subjectcanakinumab
dc.subjectfamilial Mediterranean fever
dc.subjectkidney transplantation
dc.titleEfficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score-matched cohort study.
dspace.entity.typePublication
Files
Collections
Pubmed Ek Yayınlar